openPR Logo
Press release

Scleroderma Global Market Report 2024 - By Growth, Share, Demand, Forecast To 2033

03-18-2024 08:02 AM CET | Health & Medicine

Press release from: The Business research company

Scleroderma Market

Scleroderma Market

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Scleroderma Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The scleroderma market size has grown strongly in recent years. It will grow from $2.15 billion in 2023 to $2.31 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to advances in diagnosis, immunological research, therapeutic developments, awareness and education, genetic studies.

The scleroderma market size is expected to see strong growth in the next few years. It will grow to $2.97 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to biological therapies, precision medicine, stem cell therapies, genomic and biomarker research, global collaborations. Major trends in the forecast period include digital health solutions, focus on microbiome, patient-centric care, regenerative medicine, health equity and access.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=12615&type=smp

Market Segmentation:
The scleroderma market covered in this report is segmented -
1) By Treatment: Medication, Surgery, Other Treatments
2) By Indication: Systemic Scleroderma, Localized Scleroderma
3) By End User: Hospital, Pharmaceutical Stores, Other End Users

Major Driver - Rising Scleroderma Cases Propel Therapeutics Demand
The greater prevalence of scleroderma is driving the scleroderma market going forward. Scleroderma is a chronic autoimmune disease characterized by the abnormal growth of collagen, a protein that forms the structure of skin and other tissues. An unregulated immune response, possibly triggered by various environmental factors, leads to the development of this condition. As the number of cases rises, the importance of improved diagnosis and treatment becomes evident. Scleroderma therapeutics are crucial to managing illness and alleviating symptoms by regulating the immune response and mitigating exposure to environmental risk factors. For instance, in June 2022, according to Karger Publishers, a Switzerland-based publisher of peer-reviewed journals, 19,000 people had scleroderma in the UK and 2.5 million people worldwide. Furthermore, in July 2021, a research article published by Oxford Academic Press, a university press affiliated with the University of Oxford in the UK, revealed that the global prevalence of scleroderma was 17.6 cases per 100,000 people and the incidence rate was 1.4 cases per 100,000 person-years. As a result, the greater prevalence of scleroderma is driving the scleroderma market.

Competitive Landscape:
Major companies operating in the scleroderma market report are Pfizer Inc., Johnson And Johnson Inc., F. Hoffmann-La Roche AG, Abbvie Inc., Bayer AG, Novartis AG, Merck And Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., GSK plc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Aspen Pharmacare Holdings Limited, Boehringer Ingelheim International GmbH, Principia Biopharma Corp, aTyr Pharma Inc., Cumberland Pharmaceuticals Inc., Kadmon Holdings Inc., Emerald Health Pharmaceuticals Inc., FibroGen Inc., Argentis Pharmaceuticals LLC, Corbus Pharmaceuticals Holdings Inc., Celgene Corporation, Actelion Pharmaceuticals Inc., H.A.C. Pharma

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/scleroderma-global-market-report

Top Trend - Novel Treatments Drive Scleroderma Market Growth
Developing novel treatments is a key trend gaining popularity in the scleroderma market. Major companies in the scleroderma market are developing novel drugs to manage the symptoms and sustain their position in the market. For instance, in April 2022, Tyr Pharma Inc., a US-based biotherapeutics manufacturer, received regulatory approval for its novel systemic sclerosis-related interstitial lung disease drug efzofitimod from the US Food and Drug Administration, a US-based health regulatory agency. The new drug is a First-in-class immunomodulator to downregulate and control the immune response by modulating the neuropilin-2 (NRP2) receptor to reduce symptoms of scleroderma. Additionally, Efzofitimod also targets the same immune cells responsible for the pathology of SSc-ILD (interstitial lung disease associated with systemic sclerosis) and pulmonary sarcoidosis, leading to reduced pro-inflammatory markers in a clinical study with patients suffering from pulmonary sarcoidosis.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Scleroderma Market Characteristics
3. Scleroderma Market Trends And Strategies
4. Scleroderma Market - Macro Economic Scenario
5. Scleroderma Market Size And Growth
…..
27. Scleroderma Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model"

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Scleroderma Global Market Report 2024 - By Growth, Share, Demand, Forecast To 2033 here

News-ID: 3433228 • Views:

More Releases from The Business research company

Segment Evaluation and Major Growth Areas in the Personalized Testing and Supplements Market
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future. Market Valuation and Expansion Forecast for Personalized Testing
Top Players and Market Competition in the Skin Microbiome Industry
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry. Projected Expansion in the Skin
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market Landscape
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory. Steady Growth Expected in Upadacitinib Market Size Through 2029 The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Market
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field. Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics

All 5 Releases


More Releases for Scleroderma

Rising Scleroderma Cases Propel Therapeutics Demand: The Driving Engine Behind S …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Scleroderma Market Size Growth Forecast: What to Expect by 2025? The overall volume of the scleroderma market has shown robust expansion throughout the recent past, projecting an increase from its 2024 valuation of $2.33 billion to reach $2.48 billion by 2025, reflecting a compound annual growth rate (CAGR) of
Key Factor Supporting Scleroderma Market Development in 2025: Rising Scleroderma …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. How Large Will the Scleroderma Market Size By 2025? The market size of scleroderma has notably expanded in past years. It is projected to rise from a value of $2.33 billion in 2024 up to $2.49 billion in 2025, posting a compound annual growth rate (CAGR) of 6.9%. The
Scleroderma Market Trends, Size, Share And Analysis 2024-2033
"The new report published by The Business Research Company, titled Scleroderma Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends. As per the report, the scleroderma market size has grown strongly in recent years. It will grow from $2.15 billion in 2023 to
Scleroderma Therapeutics Market, By Indication (Localized Scleroderma, Systemic …
Scleroderma therapeutics market size is projected to grow at a compound annual growth rate of 5.7% over the forecast period of 2021 to 2028. Data Bridge Market Research report on scleroderma therapeutics market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecasted period while providing their impacts on the market's growth. View Detailed Report: https://www.databridgemarketresearch.com/reports/global-scleroderma-therapeutics-market Scleroderma is a rare auto-immune disease which is generally characterized by
Scleroderma Therapeutics Market, By Indication (Localized Scleroderma, Systemic …
Scleroderma therapeutics market size is projected to grow at a compound annual growth rate of 5.7% over the forecast period of 2021 to 2028. Data Bridge Market Research report on scleroderma therapeutics market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecasted period while providing their impacts on the market's growth. View Detailed Report: https://www.databridgemarketresearch.com/reports/global-scleroderma-therapeutics-market Scleroderma is a rare auto-immune disease which is generally characterized by
Scleroderma Therapeutics Market Analysis - Forecast to 2026
As per the research conducted by GME, the Global Scleroderma Therapeutics Market will grow with a CAGR value of 6.1 percent. Moreover, the rising R&D activities along with the advancing technology and increasing government spending in the pharma industry has boosted the market and growth will be seen in the future. Browse 151 Market Data Tables and 111 Figures spread through 181 Pages and in-depth TOC on “Global Scleroderma Therapeutics Market